Bayer (FRA:BAYN) has been assigned a €125.00 ($148.81) price objective by equities research analysts at Goldman Sachs Group in a research note issued to investors on Tuesday. The brokerage currently has a “buy” rating on the healthcare company’s stock. Goldman Sachs Group’s price target would indicate a potential upside of 14.45% from the stock’s current price.
Other equities analysts also recently issued reports about the stock. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Bayer in a report on Friday, October 20th. Sanford C. Bernstein set a €129.00 ($153.57) price target on shares of Bayer and gave the company a “buy” rating in a report on Wednesday, January 17th. Independent Research set a €120.00 ($142.86) price target on shares of Bayer and gave the company a “neutral” rating in a report on Friday, October 13th. Commerzbank set a €124.00 ($147.62) price target on shares of Bayer and gave the company a “buy” rating in a report on Friday, October 13th. Finally, BNP Paribas set a €130.00 ($154.76) target price on shares of Bayer and gave the stock a “buy” rating in a research note on Monday, September 25th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of €121.71 ($144.90).
Shares of Bayer (FRA BAYN) traded up €3.50 ($4.17) during trading hours on Tuesday, reaching €109.22 ($130.02). 4,433,986 shares of the company traded hands. The company has a market cap of $90,250.00 and a P/E ratio of 29.28. Bayer has a one year low of €100.60 ($119.76) and a one year high of €123.82 ($147.40).
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.